Articles

Healthcare authorities must be updated on AMD and the importance of new therapies. A system also needs to be implemented which advises on responsibility for payment.

According to some experts, the team approach is preferable to the production-line approach when organizing a clinic that administers intravitreal anti-VEGF therapy.

Sirion Therapeutics has initiated two new Phase III clinical studies for two of its pipeline compounds, ST-601 (difluprednate) and ST-603 (cyclosporine).

The British intraocular lens (IOL) manufacturer, Rayner Intraocular Lenses, has received pre-market approval (PMA) for its C-flex lens from the FDA making it the first non-US IOL to receive FDA approval in twenty years.

Significantly more glaucoma patients, who are treated surgically rather than medically, will experience reversal of cupping.

Ellex Medical Lasers has received FDA 510(k) approval to market the Ellex 30XL laser slit lamp.

Novagali Pharma's Investigational New Drug Application (IND) to conduct a pivotal Phase III clinical trial of its dry eye candidate, Nova22007, has been granted by the FDA.

A study, which was halted before the completion of enrolment, failed to demonstrate any difference in the visual outcomes or safety concerns in patients with neovascularization secondary to age-related macular degeneration (AMD) who were treated with photodynamic therapy (PDT) in combination with either intravitreal injections of Macugen (pegaptanib sodium) or triamcinolone

QLT has announced that the Committee for Medicinal Products for Human Use (CHMP) will recommend to the European Commission that the occult indication for Visudyne be removed from the product's European label.

ISTA Pharmaceuticals has withdrawn its marketing authorization application for Vitragen.

Optical Coherence Tomography (OCT) provides a convenient and quick method of assessing the configuration of the anterior chamber.

A Swedish initiative for screening the vision of six-years olds has found that those with a visual acuity (VA) of 0.65 rarely have defects that require treatment, making the current criterion of 0.8 too demanding on the available resources.

Medennium has obtained CE mark clearance to market its photochromic intraocular lens (IOL), Aurium in Europe, making it the first lens of its kind to be introduced to the cataract lens market.

M&S Technologies has released a new software for its Smart System 2020 and PC-Plus visual acuity, contrast sensitivity and video media systems.

The US FDA has approved wavefront-guided and mixed astigmatism indications for WaveLight's Allegretto Wave Eye-Q system.

Glaucoma medication compliance and effectiveness of drug administration correlates with age and severity of disease.

Neurotech Pharmaceuticals has begun enrolment for two Phase II/III clinical trials of NT-501; it's lead Encapsulated Cell Technology (ECT) product for the treatment for retinitis pigmentosa (RP).

Alimera Sciences has announced that enrolment for its Phase III global clinical trial, FAME (Fluocinolone Acetonide in Diabetic Macular Edema), has exceeded 50%.

CoMentis (formerly Athenagen) has initiated a Phase II trial of ATG3, a topical eye drop therapy for the treatment of neovascular age-related macular degeneration (AMD).

The FDA has approved InSite Vision's New Drug Application (NDA) for AzaSite (azithromycin 1%) for the treatment of bacterial conjunctivitis.

ISTA Pharmaceuticals has received a not approvable letter from the FDA relating to its New Drug Application (NDA) for T-Pred (prednisolone acetate 1.0% and tobramycin 0.3% ophthalmic suspension).

Aspheric-based treatments with the SCHWIND ESIRIS excimer laser and ORK-CAM software offer high predictability, increases in visual acuity (VA) and no induction of aberrations.

Therapeutic interventions, in particular for neovascular age-related macular degeneration (AMD) offer a better degree of value than any other treatment right across the field of healthcare.

Cup-to-disc ratios and visual field evaluations using telemedicine-friendly devices are the most useful tools for glaucoma screening.

Carl Zeiss Meditec has united its sales and marketing activities in Germany.

Optical coherence tomography (OCT) is a useful tool for determining when re-treatments with ranibizumab are required in patients with neovascular age-related macular degeneration (AMD).

Optical coherence tomography (OCT) is an effective screening tool for wet age-related macular degeneration (AMD).

The sutureless method of transplantation of fibrin glue-coated, freeze-dried amniotic membrane (FCFD-AM) is both safe and straightforward.

Ophthalmic solutions that contain steroids are 5.8 times more likely to be contaminated than steroid-free solutions.

A Phase I/II clinical trial has been initiated to evaluate an innovative gene therapy in patients with progressive deterioration in vision caused by an abnormality in the RPE65 gene.